Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-day mortality associated with cefiderocol. We perfo...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI AG
2023-05-01
|
| Cyfres: | Antibiotics |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.mdpi.com/2079-6382/12/5/936 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|